CA2409552A1 - Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract - Google Patents

Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract Download PDF

Info

Publication number
CA2409552A1
CA2409552A1 CA002409552A CA2409552A CA2409552A1 CA 2409552 A1 CA2409552 A1 CA 2409552A1 CA 002409552 A CA002409552 A CA 002409552A CA 2409552 A CA2409552 A CA 2409552A CA 2409552 A1 CA2409552 A1 CA 2409552A1
Authority
CA
Canada
Prior art keywords
dosage form
active agent
drug
approximately
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002409552A
Other languages
English (en)
French (fr)
Inventor
Bret Berner
Jenny Louie-Helm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26699053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2409552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/024,932 external-priority patent/US20030104052A1/en
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of CA2409552A1 publication Critical patent/CA2409552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002409552A 2001-10-25 2002-10-23 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract Abandoned CA2409552A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4581601A 2001-10-25 2001-10-25
US10/045,816 2001-10-25
US10/024,932 2001-12-18
US10/024,932 US20030104052A1 (en) 2001-10-25 2001-12-18 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract

Publications (1)

Publication Number Publication Date
CA2409552A1 true CA2409552A1 (en) 2003-04-25

Family

ID=26699053

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002409552A Abandoned CA2409552A1 (en) 2001-10-25 2002-10-23 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract

Country Status (5)

Country Link
US (3) US7976870B2 (cg-RX-API-DMAC7.html)
EP (1) EP1439826A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005507000A (cg-RX-API-DMAC7.html)
CA (1) CA2409552A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003035041A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092064A1 (en) * 2005-03-04 2006-09-08 Intelgenx Corporation Delayed release pharmaceutical oral dosage form and method of making same

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2004204825B2 (en) 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
EP2535042A1 (en) * 2003-06-16 2012-12-19 ANDRX Pharmaceuticals LLC. Oral sustained-release composition comprising a macrolide
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AP2006003650A0 (en) * 2003-12-12 2006-06-30 Penwest Pharmaceuticals Co Sustained release torsemide dosage forms
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
JPWO2005094789A1 (ja) * 2004-03-31 2008-02-14 Aspion株式会社 S/o型製剤およびその製造方法
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006084164A2 (en) 2005-02-01 2006-08-10 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
PT1919466E (pt) 2005-07-11 2012-05-21 Cortria Corp Formulações para tratamento de anormalidades de lipoproteína compreendendo uma estatina e um derivado de metilnicotinamida
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2008030830A2 (en) * 2006-09-08 2008-03-13 Drugtech Corporation Sustained-release composition and method of use thereof
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
HRP20180408T1 (hr) * 2007-11-13 2018-04-20 Meritage Pharma, Inc. Pripravci za liječenje gastrointestinalnih upala
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
BRPI0914080A2 (pt) 2008-10-08 2015-10-27 Bioplus Life Sciences Pvt Ltda "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010129686A1 (en) 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
SI2456424T1 (sl) 2009-07-22 2013-10-30 Gruenenthal Gmbh Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
WO2011027346A1 (en) * 2009-09-03 2011-03-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A gastroretentive dosage form for oral treatment of domestic animals
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6076913B2 (ja) 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP2014524925A (ja) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
CN102579344B (zh) * 2012-03-02 2014-02-26 海南美兰史克制药有限公司 氯沙坦钾脂质体固体制剂
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3378472A1 (en) 2012-08-09 2018-09-26 Dynamis Therapeutics, Inc. Combinations of meglumine
EP2890760A4 (en) 2012-08-30 2016-10-12 Atrp Solutions Inc DOUBLE MECHANISM THICKENERS FOR HYDRAULIC FRACKING FLUIDS
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
WO2014100077A1 (en) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Gastro-retentive formulations
PT2941233T (pt) 2013-01-07 2020-11-13 Univ Pennsylvania Composições e métodos para tratar linfoma cutâneo de células t
CA2899349C (en) 2013-02-04 2021-09-21 ATRP Solutions, Inc. Salt-tolerant star macromolecules
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3613861A1 (en) 2013-07-02 2020-02-26 EcoPlanet Environmental LLC Volatile organic compound formulations having antimicrobial activity
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
MY176976A (en) 2013-10-10 2020-08-28 Bausch Health Ireland Ltd Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
JP6932506B2 (ja) 2013-11-26 2021-09-08 イエール ユニバーシティ 細胞透過組成物およびそれを用いる方法
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2015157262A1 (en) 2014-04-07 2015-10-15 Women & Infants Hospital Of Rhode Island Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
RU2016151697A (ru) 2014-06-02 2018-07-10 Тева Фармасьютикал Индастриз Лтд. Расправляемая удерживаемая в желудке лекарственная форма
CN106573015B (zh) * 2014-06-11 2021-11-26 麻省理工学院 肠溶弹性体
MX385886B (es) 2014-07-03 2025-03-18 Pilot Polymer Tech Inc Macromoleculas estrellas compatibles con tensoactivos.
CN106714809A (zh) 2014-08-20 2017-05-24 耶鲁大学 对治疗或预防肝脏疾病或障碍和促进体重减轻有用的新型组合物和方法
JP6932641B2 (ja) 2015-03-06 2021-09-08 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
KR20180014778A (ko) 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
KR102207539B1 (ko) 2015-06-30 2021-01-26 네우라드 리미티드 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
CN108135835A (zh) 2015-08-06 2018-06-08 约翰霍普金斯大学 用于治疗代谢紊乱的组合物和方法
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
JP2018537093A (ja) 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
EP3448369B1 (en) 2016-04-29 2025-06-25 The Regents of The University of Colorado, A Body Corporate Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
AU2017321791B2 (en) 2016-09-01 2022-03-24 Mebias Discovery, Inc. Substituted ureas and methods of making and using same
AU2017353986B2 (en) 2016-11-07 2021-08-19 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
US10737079B2 (en) 2016-12-02 2020-08-11 Clexio Biosciences Ltd. Gastric residence system
US10941126B2 (en) 2017-01-19 2021-03-09 Temple University-Of The Commonwealth System Of Higher Education Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
EP3601216B1 (en) 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
US11166953B2 (en) 2017-04-17 2021-11-09 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
ES2928071T3 (es) 2017-06-16 2022-11-15 Amneal Complex Products Res Llc Formas de dosificación gastrorretentiva para el suministro sostenido de fármacos
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
KR20200072478A (ko) 2017-09-08 2020-06-22 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Her-구동된 약물-내성암의 치료 또는 예방을 위한 화합물, 조성물 및 방법
CN111655230A (zh) * 2017-11-07 2020-09-11 拉尼医疗有限公司 使用可吞服药物递送装置递送到肠道组织中的凝血因子制剂
EP3716985A1 (en) 2017-11-27 2020-10-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
IL275444B2 (en) 2017-12-18 2025-01-01 Tris Pharma Inc Modified release drug powder formulation containing gastric-retaining raft-forming systems with pulsed drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
WO2019126125A1 (en) 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
EP3743060A4 (en) 2018-01-24 2021-11-03 The Rockefeller University ANTIBACTERIAL COMPOUNDS, RELATED COMPOSITIONS AND THEIR METHODS OF USE
KR20200116110A (ko) 2018-01-29 2020-10-08 듀크 유니버시티 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법
BR112020024048A2 (pt) 2018-05-25 2021-02-17 Temple University-Of The Commonwealth System Of Higher Education composição, e, métodos para descolonizar um organismo microbiano, para destruir ou interromper ou inibir ou reduzir a formação de biofilme de um organismo microbiano e para tratar uma infecção microbiana em um indivíduo.
US11091473B2 (en) 2018-05-29 2021-08-17 Acadia Pharmaceuticals Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
EP4056172A1 (en) 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
MX2021001877A (es) 2018-08-17 2021-07-15 Univ Pennsylvania Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
WO2020081762A1 (en) 2018-10-19 2020-04-23 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
KR20210148078A (ko) 2019-01-30 2021-12-07 사니핏 테라퓨틱스 에스.에이. 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
JP2022538767A (ja) 2019-06-12 2022-09-06 ザ ウィスター インスティテュート アセチルCoAシンテターゼ2(ACSS2)阻害剤およびそれを使用する方法
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
EP4236924A4 (en) * 2020-10-30 2024-10-09 Triastek, Inc. DOSAGE FORMS OF MEDICATION TO BE RETAINED IN THE STOMACH
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
MX2024001390A (es) 2021-07-30 2024-05-17 Evecxia Therapeutics Inc Formas de dosificacion gastrorretentivas de 5-hidroxitriptofano.
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
JP2025525092A (ja) 2022-07-29 2025-08-01 サニフィット・セラピューティクス・ソシエダッド・アノニマ 異所性石灰化の治療、進行の阻害、および予防に使用するためのip4-4,6置換誘導体化合物
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
CN115184371B (zh) * 2022-08-05 2023-04-25 深圳市俱进纸品包装有限公司 一种礼盒印刷的瑕疵视觉检测装置
KR20250059489A (ko) 2022-09-06 2025-05-02 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물
KR20240108663A (ko) * 2023-01-02 2024-07-09 일양약품주식회사 베타네콜을 함유하는 안정한 방출 제어형 약제학적 조성물 및 이의 제조방법
TW202513071A (zh) 2023-08-14 2025-04-01 以色列商琉璃藥品 (1991) 有限公司 Gal475組合物及其使用方法
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
DE4209160A1 (de) * 1992-03-20 1993-09-30 Bauer Kurt Heinz Prof Dr Vernetzte Polysaccharide, Verfahren zu ihrer Herstellung und ihre Verwendung
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5382435A (en) * 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
GB9326267D0 (en) * 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
EP0830129B1 (fr) 1995-04-14 2002-03-20 Pharma Pass Compositions solides contenant du polyethyleneoxyde et un principe actif non amorphe
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6048547A (en) 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
KR100321489B1 (ko) * 1996-07-08 2002-10-09 에드워드 멘델 컴파니 인코포레이티드 고용량의불용성약물용서방성매트릭스
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
EP0951279A1 (en) * 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6120803A (en) * 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (cg-RX-API-DMAC7.html) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
TW357614U (en) 1998-03-12 1999-05-01 Wen-Neng Liu Retractable safety syringe needle for hypodermic injection
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
WO2000038650A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Gastric retention dosage form having multiple layers
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
EP1790334A3 (en) 1999-11-02 2008-02-20 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
TWI259836B (en) 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092064A1 (en) * 2005-03-04 2006-09-08 Intelgenx Corporation Delayed release pharmaceutical oral dosage form and method of making same

Also Published As

Publication number Publication date
US20110301129A1 (en) 2011-12-08
US9980903B2 (en) 2018-05-29
WO2003035041A1 (en) 2003-05-01
US7976870B2 (en) 2011-07-12
JP2005507000A (ja) 2005-03-10
EP1439826A1 (en) 2004-07-28
US20040185105A1 (en) 2004-09-23
US20130149379A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
US7976870B2 (en) Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040156899A1 (en) Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) Formulation of an erodible, gastric retentive oral diuretic
US9937142B2 (en) Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
AU2008282900B2 (en) Pulsatile gastric retentive dosage forms
US20160000721A1 (en) Gastro-retentive formulations
MXPA04003930A (es) Forma de dosificacion oral retentiva gastrica con liberacion limitada de medicamento en el tracto gastrointestinal inferior.
HK1158064B (en) Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
HK1158064A (en) Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued